10-QPeriod: Q3 FY2014

PFIZER INC Quarterly Report for Q3 Ended Sep 28, 2014

Filed November 6, 2014For Securities:PFE

Summary

Pfizer Inc.'s Q3 2014 report shows a slight decrease in revenues compared to the previous year, primarily due to the loss of exclusivity for several key products and the expiration of collaboration agreements, which significantly impacted alliance revenues. Despite the revenue dip, the company managed to slightly increase its income from continuing operations, driven by factors like lower restructuring charges, favorable royalty-related income from Enbrel, and a lower effective tax rate. The company also highlighted growth in specific products like Lyrica, Prevnar, Xalkori, and Xeljanz, and positive performance in emerging markets, signaling a strategic shift towards innovation and growth areas. Looking ahead, Pfizer is focusing on its pipeline and business development initiatives, including the recent acquisition of InnoPharma and collaborations in oncology. The company reaffirmed its financial guidance for the full year 2014, demonstrating confidence in its strategic direction despite the ongoing challenges of patent expirations and a competitive market environment. Investors will be watching Pfizer's ability to drive growth from its newer products and R&D pipeline to offset revenue declines from mature products.

Financial Highlights

54 data points
Beta

Revenue

$12.36B

80.8% Gross Margin

Net Income

$2.67B

21.6% Net Margin

EPS (Diluted)

$0.42

Total Assets

$171.36B

Cash & Equivalents

$2.44B

Free Cash Flow

$4.19B

Financial Statements
Beta
Revenue$12.36B
Cost of Revenue$2.37B
Gross Profit$9.99B
SG&A Expenses$3.56B
Operating Income$7.84B
Interest Expense$343.00M
Net Income$2.67B
EPS (Basic)$0.42
EPS (Diluted)$0.42
Shares Outstanding (Basic)6.33B
Shares Outstanding (Diluted)6.40B

Key Highlights

  • 1Total revenues for Q3 2014 were $12.36 billion, a 2% decrease from $12.64 billion in Q3 2013, primarily due to product exclusivity losses and expiring collaborations.
  • 2Income from continuing operations increased slightly to $2.68 billion in Q3 2014 from $2.59 billion in Q3 2013, driven by lower expenses and a lower effective tax rate.
  • 3Research and development expenses increased by 11% year-over-year for the quarter, reflecting investment in new drug candidates and late-stage programs.
  • 4The company completed the acquisition of InnoPharma for $225 million plus contingent payments, aiming to strengthen its sterile injectables portfolio.
  • 5Key products showing strong operational growth include Lyrica, Prevnar family, Xalkori, and Xeljanz.
  • 6Pfizer maintained its full-year 2014 financial guidance, signaling confidence in its strategic initiatives despite market challenges.
  • 7The company continued its share repurchase program, buying back approximately 43.5 million shares in the third quarter.

Frequently Asked Questions

The primary driver for the revenue decline was the loss of exclusivity for several key products (e.g., Detrol LA, Viagra, Aricept) and the expiration of co-promotion agreements, notably for Enbrel and Spiriva, which significantly reduced alliance revenues.

Pfizer managed to increase income from continuing operations due to several factors: lower restructuring charges and acquisition-related costs, an increase in royalty-related income (primarily from Enbrel), a decline in certain significant items like an estimated loss related to an option to acquire Teuto, and a lower effective tax rate.

Pfizer's key growth drivers include products like Lyrica, the Prevnar family of vaccines, Xalkori, and Xeljanz. Strategically, the company is focusing on its R&D pipeline, business development initiatives such as acquisitions and collaborations (e.g., InnoPharma, Cellectis), and growth in emerging markets to offset declines from mature products.

Pfizer reaffirmed its full-year 2014 financial guidance, indicating a projected adjusted diluted EPS between $2.23 and $2.27. This suggests continued confidence in its operational performance and strategic initiatives, even while navigating challenges like generic competition.